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Doxorubicin is an anthracycline antibiotic extracted from the bacterium 
Streptomyces peucetius. Its cytotoxic effect produced by intercalating with DNA 
causing breakdown of DNA strand which causes cancer cell apoptosis. Despite 
being an effective anticancer agent it causes several crucial side effects like carditox-
icity, neuropathy, hepatotoxicity, nephrotoxicity, alopecia, typhlitis, myelosuppres-
sion, neutropenia, anaemia, thrombocytopenia, nausea, and diarrhoea were caused 
mainly due to the inability to distinguish between cancer cells and normal cells. This 
chapter mainly focuses on doxorubicin’s side effects, current understanding of the 
molecular mechanisms, and management and preventive strategies of doxorubicin’s 
cardiotoxicity during the treatment of various type of cancer.
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1. Introduction
1.1 Historical background
In the 1950s Italian based company; Farmitalia research laboratory began a 
research program in finding the anticancer compounds from soil-based microbes. 
In the process of research collected a soil sample from the castle named as castle Del 
monte, which was built in the 13th century. The collected soil sample contains new 
strains of bacterial species and isolated from it. The separated microbe recognised 
with the name Streptomyces peucetius which is typically produces a significant red 
pigment. The antibiotic produced from this bacterium discovered to be efficient in 
treating the tumours especially solid tumours while researching on mice. Since a 
group of French scientists found the same compound about at the same time, they 
agreed to call the antibiotic daunorubicin, referring to the two nations. In which, 
Dauni refers to the pre-Roman tribe who inhabited the position in Italy where the 
species of bacteria were isolated and ruby represents the colour in Italy. The clinical 
trials of daunorubicin were began in 1960s and confirmed as successful in treat-
ing the lymphoma and acute leukaemia [1, 2]. After a short note of the time, in 
1967 daunorubicin was discovered to be cause fatal cardiotoxicity. Then, by using 
nitroso-N-methyl urethane, the Italian research company mutated the strains of 
Streptomyces peucetius and developed a new strain of bacterial species that pro-
duces 14-hydroxylated daunorubicin, also known as Adriamycin (named after the 
Adriatic Sea), then changed its name to doxorubicin, which has a strong therapeutic 
index, but cardiac toxicity remains [3].
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1.2 Doxorubicin chemical structure and properties
Doxorubicin (DOX) is an anthracycline antibiotic structurally similar to 
Daunorubicin as natural anti-cancer antibiotic used in cancer treatment. Its anti-
cancer effect produced intercalating with DNA and this will inhibit DNA transcrip-
tion and replication; and by binding to the topoisomerase II enzyme and inhibit 
the resealing of the DNA fragments. The presence of sugar moiety attached to the 
anthracycline ring further enhances the binding to phosphate and sugar moieties 
in to DNA. This led to stops the proliferation of cancer cells in the host [4]. Besides, 
the presence of quinone moiety apart from contributing the cytolytic ability by 
generating the intermediate radicals, which further react with the oxygen and forms 
superoxide ions and these ions also shows a high tendency towards the damaging 
the cell membranes causes a dose-dependent the cardiac myopathy [5, 6].
The Doxorubicin is mainly used in case of patients suffering from Breast cancer, 
ovarian cancers, lung cancers, bladder cancers, leukaemia (acute lymphoblastic 
leukaemia, acute myeloid leukaemia) and AIDS-related Kaposi’s sarcoma and various 
solid tumours. DOX also used in combination with other agents in case of bone sarco-
mas, soft tissue sarcomas, uterus cancer, endoblastoma cancer, cervix cancer, pancre-
atic cancer, Ewing’s sarcoma, mesothelioma, multiple myeloma, Wilms tumour and 
in neuroblastoma [7, 8].
2. Doxorubicin side effects
2.1 Hepatotoxicity
Liver is one of the essential organs of the body; it plays a major role in metabolism 
and detoxification of several drugs. This can explains why liver is the primary body 
organ affected by chemotherapy. Despite being cytostatic and cytotoxic effects on 
cancer cells DOX documented to accumulate in the various tissues include liver cells. 
In humans, it is estimated as 50% of DOX eliminated in un-exchanged form, the 
remainder dose metabolised through hydroxylation, semiquinone formation [9]. The 
major pathway for biotransformation of DOX is catalysed by the NADPH-dependent 
carbonyl reductase, Nitric oxide synthase, cytochrome P-450 reductase, aldo-keto 
reductase enzymes. The hydroxylation occurs at C-13 carbon in group commonly reac-
tion referred as electron reduction forms the secondary alcohol metabolites [10–13].  
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The metabolized intermediates in the presence of oxygen converted to carbonyl 
moieties resulting in generation of Superoxide anions and hydrogen peroxides causes 
peroxidation of lipids in membranes of cell, aggregation of proteins (Figure 1) [13–15].
The regenerative capacity of liver is more can cure the damage caused by various 
agents such as DOX, which causes damage and decreases the regeneration of liver cells 
by increasing the oxidative stress due to the radical generation by oxidation in hepa-
tocytes. The generated radical causes decrease in GSH levels, damages in DNA and 
also act as secondary metabolites in in many metabolic pathways which includes in 
cell proliferation and cell death [16–18]. To overcome such situations liver employs the 
efflux mechanisms, the efflux of DOX is achieved through from liver by ATP depen-
dent ABC proteins (P-glycoprotein) which increase the efflux of the intracellular DOX 
and maintain the homeostasis. The mechanism uses large quantity of energy but with 
the presence of the DOX in liver cells decreases the ATP production and increases the 
ADP and Pi within the cells [19–21]. Due to this effect sometimes liver cells can’t able 
to regenerate from DOX induced effects and causes hepatotoxicity.
2.2 Nephropathy
Besides maintaining the homeostasis by regulating the body fluids, kidneys work 
to reabsorb the low concentrations general constituents in the body and also remove 
the foreign substances like drugs or other kinds of agents. For this kind of reasons 
kidneys considered as metastatic organs of human beings [22]. The regenerative 
capacity of the kidneys is low when compared to the liver and highly susceptible to 
Figure 1. 
DOX mediated effects on the liver.
Advances in Precision Medicine Oncology
4
epithelial degeneration occurs at renal glomerulus where the filtration occurs may 
lead to the glomerulosclerosis [23].
DOX interferes with the glandular podocytes of the kidney and cause nephropa-
thy the most accepted mechanism behind the nephropathy is an accumulation of 
proteinuria in the kidney by the local passage of leaked proteins [23]. Increase in 
the structural changes in nephrons causes hypertension, steroid resistance, high 
incidents of renal failure and glomerular vacuolization, inflammation, tubular 
dilation, intestinal fibrosis, permeability differences in the glomerulus, and certain 
conditions like hypoalbuminemia, dyslipidemia, hypercoagulation, size differences 
in kidney most likely observed [24]. A study conducted on the DOX effect on the 
mitochondria by the Lebrecht suggested that DOX interfere the mitochondrial 
mtDNA in the kidney with ROS produced from it and accelerating the damaging of 
the nephron. Another study reports suggesting that DOX forming an iron-mediated 
anthracycline complex, which produces the ROS led to an increase in the oxidative 
lesions in the cells causing damage to the critical cellular components [25, 26].
The decreasing the levels of the GSH (Glutathione), vitamin E levels and other 
natural oxidant levels production from the liver cells enhances the nephropathic 
conditions which may initially affect the Bowman’s capsule thickness and the 
glomerular tuft of the nephron. The study conducted by Rook et al. [26] Reported 
as Angiotensin-converting enzyme is said to be one of the responsible factors for 
tissue damage triggered by the DOX therapy. The ACE is causing the pro-inflam-
matory, pro-fibrotic effects which make interference in the kidney and nephrons to 
maintain the glomerular pressure and filtration rate of blood [27, 28]. The cases of 
nephropathy and proteinuria are rare in humans susceptibility towards such condi-
tion based on the genetic makeup of the individual.
2.3 Neurotoxicity
The brain is the largest and most complex organ in the human body contains 
about 100 billion neurons with 1 trillion established connections throughout the 
body. DOX is not able to transfer through the blood–brain barrier (BBB), therefore 
DOX effects against the brain via indirect way [29, 30]. These effects include: 
depression, anxiety, decrease in motor functions, haemoglobin levels, perception 
skills affected, and menopausal status, visuospatial skills are affected through 
cancer chemotherapy. The recovery of the cognitive functions may take up to a year 
[31]. The DOX mediate increase TNF-α level (inflammatory cytokines produced 
by the macrophages/monocytes during the acute inflammation involved in many 
signalling pathways) in the brain at cortex and hippocampus of mice [32–34]. The 
mitochondrial activity, glutathione-S-transferase, GSH levels, and MnSOD levels in 
the brain are decreased and increase in levels of 4-hydroxynoneal (HNA), thiobar-
bituric acid reactive substances (TBARS), malondialdehyde (MDA) and increase in 
levels of protein carbonyl groups [35–38], which causes increase the oxidative stress 
in the brain cells and further led to cause cell damage.
The MnSOD levels in the brain generally detoxify the oxygen free radicals, inac-
tivated by the Nitric oxide (NO). The DOX indirectly increased the concentration 
of NO by overexpressing the Nitric oxide synthase enzyme [37]. A study conducted 
on the NOS dependent brain injury with DOC reinforcing the nitric oxide tissue 
damage [38]. The mitochondrial activity is very important in the brain because it is a 
powerhouse of cells (energy production) brain uses 20% of body glucose for energy 
production to conduct and maintain the regular activities [39]. The DOX induces 
generation of MDA, TBARS, and HNA which cause the decrease the mitochondrial 
activities. A study conducted on the DOX-induced toxicity on rats with 10 mg/kg 
dose, the rats died between 10 and 50 days with observed light microscopic studies 
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reveals that specific changes in the ganglionic cells of the peripheral nervous  
system [40].
2.4 Cardiomyopathy
This side effect found to be a dose-dependent on DOX. The DOX-induced car-
diotoxicity occurs acutely and chronically. The acute effects occur within one week 
period the patient may experience arrhythmia, hypotension, and super ventricular 
tachycardia. These abnormalities are generally reversible in a noticeable period 
[41]. The chronic effects are shown in only 1.7% of patients with a 50% mortality 
rate [42, 43]. The chronic effect of DOX such as congestive heart failure reported 
in a study, when the patients are treated with dose 500–550 mg/m2 in more than 
4% of patients when treated with the dose is 551–600 mg/m2 18% of patients 
cause the CHF, and almost 35% of patients observed with CHF when treated with 
>601 mg/m2 [44, 45].
A study conducted by the Zordosky and EI-kadi on DOX-induced toxicity 
reported as the induction of Brain natriuretic peptides, atrial natriuretic peptides 
genes, monooxygenases, cytochrome P genes and hypertrophy markers respon-
sible for the xenobiotics and certain endogenous substances [46]. The inductions 
of these genes are cause cardiac hypertrophy leading to heart failure and altered 
the arachidonic acid mechanisms. A study reported the DOX effects based on the 
concentrations, at low concentrations DOX dose (o.5–1 μM) causes the alterations in 
structural proteins (includes sarcomeric myosin, nuclear lamina), plasma mem-
brane blebbing (causes change in cell shape), and mitochondrial depolarization 
and fragmentation. At high concentration causes (5–50 μM) causes the cytoplasm 
vacuolization, swelling of mitochondrial cells, promote the cellular alterations 
(Figure 2) at the cellular and nuclear membranes [47]. The DOX reportedly binds 
Figure 2. 
DOX-mediated effects on the Heart.
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to the cardiolipin (a mitochondrial inner membrane component), which raises 
the accumulation of the DOX inside the mycoplasma when compared to the other 
body cells. The high concentration existence of the NADPH dehydrogenase inside 
the mitochondria initiates the redox reaction in the complex and promotes the 
production of the Reactive oxygen species. Myocytes are generally having low levels 
of anti-oxidants when compared to the other tissue cells, considerably DOX shows 
enhanced effects on the heart and cause toxicity [48–50].
The antioxidant level differences were observed in rats under DOX treatment 
based on the age differences, younger Fischer rats contain more levels of antioxidants 
when compared to old Fischer rats. A recent study stated the involvement of the 
Toll-like receptor TLR-4 (a specific receptor in the immune system generally recognise 
the multiple bacterial antigens and plays a major role in the maturation of the phago-
somes) [51]. The increase in TLR-4 expression in the DOX-induced Cardiomyocytes, 
when studied the cardiomyopathic cells in humans and animals. The deficiency of 
TLR shows decreased in lipid peroxidation and nitrotyrosine levels in cardiomyop-
athic cells. The other study on the glutathione peroxidase 1 (GPx) enzyme is present 
in both cytosol and mitochondria play a major role in the detoxification. The study 
conducted with the insertion of DOX on non-GPx and wild type mice, the results 
showed based on the study on myocytes of the non-GPx mice having the high concen-
tration of the DOX deposits in cells, when compared to wild type mice [52–54].
The oxidative stress is a major cause for the exhibiting the cardiotoxicity, 
involved the generation of higher amounts of ROS cause the cellar alterations and 
damage are referred to as oxidative stress. The ROS is countered by the anti-oxidant 
system in the body, in cancer patients under the DOX chemotherapy observed the 
decreased the levels of GSH, TRAP levels in the body. The ROS is generation is 
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Under stress conditions, oxygen radical facilitates the ferrous iron from the 
ferric ion. The iron, under normal conditions sequestered within the ferritin (a 
globular protein and forms the nanocage with the metal-protein complexes) but 
with regards to DOX when converted to its semi-quinone form complexes with 
iron-free radical and converted to DOX forms while generating the oxygen free 
radical. The generated complexes block the iron-free regulating proteins (IRP), 
and then these IRPs bound to the iron-responsive elements in mRNA ferritin. The 
tremendous amounts of free iron releases and gain complexes with the DOX. This 
specific condition magnifies the production of ROS in cells [57–59].
The ROS acts as secondary signalling molecules shows direct effects on the 
lipids, proteins, DNA, and RNA in various pathways involved in cell proliferation, 
cell death and maintain the homeostasis. It is domineering to maintain the levels of 
ROS in the body, in case of the heart the effect is maximum by ROS due to lack of 
efficient levels of anti-oxidants in myocytes. The conditions such as cellular hyper-
trophy, alterations in the gene expressions, ventricular remodelling, the extracel-
lular matrix of the mitochondria transformation, calcium transient perturbation 
and cell death activation such kinds of pathological changes may be observed in 
myocytes lead the death of cells.
2.5 Mechanisms involved at different levels of cardio toxicity
2.5.1 Cellular hypertrophy
A particular disorder marked by an increase in cell size and volume. The abnor-
mality shows an improvement in the degree of protein synthesis, increased in the 
organisation of sarcomere (contractile muscle fibre unit). At molecular level induc-
tion of hypertrophy associated genes are triggered by the DOX treatment which are 
alpha myosin heavy chain, ventricular myosin light chain-2, and atrial natriuretic 
peptide genes [60]. The main signalling cascades of the hypertrophy are tyrosine 
kinases, PI3K/Akt [61], and NF-𝜅B [62, 63], protein kinase C (PKC), mitogen-
activated protein kinases (AMPK [64]; ERK1/2 [65], p38 [66], and JNK) which are 
increased in DOX therapy induce cellular hypertrophic conditions [67].
2.5.2 ECM remodelling
Extra cellular matrix is a molecular network consisting of glycol conjugates, 
proteins, glycosaminoglycans and adhesive receptors that associate with each other 
and forms frame network, where cells reside on them [68]. The ECM frame work is 
present in all tissues it continuously shifts in quantitative and qualitative terms on a 
daily basis. In case of myocytes ECM is essential for attachment, alignment and ori-
entation facilities the cellular contractions in myocytes. Changes in the ECM of the 
heart found in DOX treatments, the symptoms of DOX are related to the activation 
of the Membrane Metalloproteinase enzymes MMP-2 & 9 in 4 weeks of treatment 
[69]. Changes in MMP-2 activate the Akt channels; suppress the superoxide dis-
mutase enzyme, which raises the amount of superoxide levels, and induce caspase-3 
and all other agents together promote remodelling and apoptosis [70].
2.5.3 Impaired cardiac contraction
The heart cells (cardiomyocytes) composed of myofibrils with typical con-
traction and relaxation. Pump and propel the blood to systemic circulation. 
Myofibrils contain multiple contractile units called sarcomere, which have actin 
and myosin filaments. In a calm state, actin is coated in tropomyosin and protects 
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the myosin-binding sites. The troponin and tropomyosin are attached when the 
calcium enters into the cytosol from the sarcoplasmic reticulum; calcium binds to 
the troponin and the position of the tropomyosin and troponin changes resulting in 
shortening of the sarcomere. That specific condition termed as cardiac contraction 
controlled by calcium influx and myofilaments. DOX could affect the transcrip-
tion and expression of the specific proteins [71]. Transcription factor-like GATA4 
for the regulation of sarcomeric synthesis and cardiac differentiation and survival 
of myocytes. DOX-induced ROS decreases binding function, disrupts sarcomere 
structure, contractile reduction and myofibrillar deterioration [72]. DOX is believed 
to interact with calcium homeostasis by modifying the ion pump and modifying the 
ion channel movement, resulting in lipid peroxidation. ROS quickly targets the fatty 
acids of the membrane lipids and disrupts the mitochondrial calcium channels by 
increasing the activity of the voltage-sensitive L-type calcium channels on the cell 
membrane resulting in accumulation of calcium [73]. Calcium overload throughout 
cytosol, Causes the disruption in the contraction and relaxing of cardiomyocytes.
2.5.4 Cell death
The general apoptosis is a process where a cell commits to suicide, damage to 
genetic material, protein, cellular organelles that beyond the repair would trigger 
the suicide to save the energy and resources. Apoptosis firmly regulated process 
involves intrinsic mitochondrial apoptosis, extrinsic death receptor pathways 
[74]. The mitochondrial pathway relays on the Trans membrane potential is a key 
indicator of membrane permeability. It is assumed that permeability can be either 
permeability-dependent or independent of the pore transition [PT]. The PT pore 
consists of the adenine nucleotide translocator, matrix protein cyclophilin D, and 
voltage-dependent anion channel. The opening of the PT pore activates the dis-
sipation of the proton gradient produced by electron transport, resulting in the 
uncoupling of oxidative phosphorylation. The opening of the PT pore also allows 
water to penetrate the mitochondrial matrix, resulting in the swelling of the inter-
membrane space and the rupturing of the outer membrane allowing the release of 
apoptogenic proteins. Released proteins include cytochrome c, apoptosis-inducing 
factor and endonuclease G. Cytochrome c in conjunction with apoptosis protease 
activating factor (APAF-1) and pro-caspase 9 forms an apoptosome, which in turn 
activates effector caspases that collectively facilitate the execution of apoptosis. Due 
to decrease in the number of normal cardiomyocytes is significantly reduced, the 
heart failed to pump the blood sequentially ventricular remodelling and death of 
myocytes [75].
The death receptor pathway involves the binding of death ligands such as FasL, 
TNF-α to their respective membrane-bound receptors. The bonded ligands signals 
to various proteins mediate the cascade, which leads to apoptosis of the cell [76]. 
In cancer therapy, DOX-induced ROS activates the p38, p53 and NF-kB pathways 
resulting in the differences in pro- and anti-apaptonic signalling imbalance, such 
imbalance cause release of cytochrome C from mitochondrial membrane proteins, 
subsequently lead to apoptosis of cell [77, 78].
2.5.5 Autophagy
Autophagy is a method of restoring or repairing the destroyed cells. It is a 
self-degrading mechanism (survival mechanism) to maintain a balance of life 
in response to dietary stress, energy depletion. Autophagy destroys malformed 
proteins, weakened organelles, and other cell infections, which can be unique 
or non-specific, but processes are not completely thought out. Under diseased 
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environments, autophagy either facilitates cell death or induces cell death depend-
ing on the demands of different people [79, 80]. In DOX-based therapy toxicity 
mediated autophagy by suppressing GTAT4 expression and activating S6K1, this 
plays a direct and indirect role in autophagy control. Autophagy varies due to spe-
cies differences; autophagy dependent on DOX is increased in mice but decreased in 
autophagy has been seen in mouse cases [81–84]. The autophagy achieved in DOX 
therapy via several mechanisms, such as ATG 5 & 12 is the inhibitors of the Bcl-2 
family, which regulate the cytochrome release from the mitochondria. Cytochrome 
C releases the caspase-9 lead to the autophagosome, can regulate the apoptosis. In 
some other studies, autophagy reduces the DOX-induced cardiotoxicity by decreas-
ing mitochondrial ROS formation.
2.6 Diagnosis
The DOX-induced cardiomyopathy consists of a complete examination of the 
cardiovascular system for detecting the symptoms, such as S3 gallop and elevated 
jugular vapour pressure, T wave impairments; low voltage QRS complexes are 
measured.
• Electrocardiography combined with Doopler studies used to study early 
diagnostic symptoms of the cardiac myopathy through the measure of  
latero-ventricular dysfunction.
• Radionuclide ventriculography used to access the latero-ventricular systolic 
and diastolic function. Observes the cardiac adrenergic denervation occurs in 
case of doxorubicin induced cardiomyopathy.
• Metaiodobenzylguanidine based nuclear imaging can be employed to 
assess cardiac adrenergic denervation occurred trough the DOX based 
cardiomyopathy.
• The DOX treated patients are sensitive to the indium labelled monoclonal 
antimyosin antibodies (myosin an ATP dependent superfamily of motor 
proteins major role in muscle contraction and motility) used to detect the 
cardiac myopathy, myocarditis, chagas heart disease ischemic myocardium, 
and kawasaki heart disease [85].
• The measurement of the cardiac enzymes and neurohormones are used for 
detecting the heart failure but not a characteristic feature of the DOX-induced 
cardiomyopathy [86].
• The presence of endomyocardial biopsy is the best route for detecting the 
DOX-induced diseases, according to the grade of biopsy severity of the disease 
is measured [87, 88]. It is invasive and requires experience for recognising the 
results become a disadvantage for this technique.
3. Management & preventive strategies for doxorubicin cardiotoxicity
The DOX has an extreme side effect like cardiotoxicity, but is still in use because 
of its efficacy in the treatment of cancers. Toxicity can be avoided in several ways. 
Many studies have shown that cardioprotective agents can achieve a reduction in 
cardiotoxicity. A recent research on HSP-20 (heat-shock protein) has shown that the 
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protection of Akt activity prevents the cardiotoxic effect caused by DOX [89–92]. 
Different kind of agents is used to control the DOX effects such as Dexrazoxane 
(DZR); it contains bisdioxopiperazine rings falling under alpha-amino acid and the 
derivative compound also known as cardioxane or Totect or Zincard. A promising 
compound that activates after hydrolysis and resembles the EDTA structure after 
conversion makes complexes with Iron and reduces the incidence of anthracycline-
iron complexes, thus preventing ROS generation in myocytes. Dexrazoxane has 
also been known to contain the Topoisomerase II enzyme function and inhibit the 
tumour cell growth. Used mainly for the activities of iron-chelating agent, cardiac 
protection, anti-neoplastic activities, and chemo protection. Indirectly active in 
chromatin remodelling complexes by activating vitamin D receptors. DZR is often 
known to provide up-regulation of the ERK and Akt pathways to guard against 
cardiomyopathy [93–96] but DZR is not approved for routine use in patients with 
metastatic cancer and other forms of cancer, as stated by the American Clinical 
Oncology Society [98, 99]. DOX was analysed in association with DZR for 10 years 
in women with breast cancer [100]. No, people suffer from heart disease over the 
time and there are no records of adverse effects with respect to the heart.
Diuretics are used to avoid signs of systemic and pulmonary ventricular obstruc-
tion, and medications dependent on β-adrenergic receptors are used depending on 
the type of systolic heart problem [97]. Metoprolol is safe and effective in the treat-
ment of cardiac myopathy [98], angiotensin II is also recommended for advanced 
heart disease cases, and low-dose isosorbide dinitrate substituted angiotensin 
inhibitor medication is favoured and hydralazine is favoured for cardiomyopathic 
myopathy.
The successful release of DOX at a particular site of operation is another form 
of preventive step. Like liposomal dosage formulations, the specified delivery 
mechanism passively decreases the impact caused by non-cancerous cells. For 
liposomes drug interaction with blood and cancer cells, structural characteristics 
such as vesicle size, pharmacokinetic characteristics such as stability and pharmaco-
dynamic characteristics such as plasma clearance are important. Tumour cells have 
conditions that favour high-level depositions, because newly developed cells have 
microvasculature-permeable vessels, which contain poor lymphatic drainage, low 
levels of lipase enzymes and other oxidising agents. Due to these features of cancer 
cells shows aggregation. Once liposomes enter the tumour cells the differences in 
the intestinal pH favours the release of drugs constituents. The pH of cancer cells 
is differ from other normal cells because of this the drug is preferentially released 
in tumour cells and avoid the toxicity in non-cancer cells. The recently reported 
formulation of polyethylene glycol-coated liposomal doxorubicin (PLD) shows 
better pharmacokinetics relative to general formulations and has fewer side effects 
[101]. A phase clinical trial of 50 mg/m2 PLD administration in patients with carci-
noma with a demonstrated history of platinum-based chemotherapy at intervals of 
4 weeks reported low toxicity. The other formulation like poly (ethylene oxide)-b-
poly (e-caprolactone-DOX) [PEO-b- P(CL-DOX)] prevents the premature release 
outside of the tumor cells [102].
The development of analogues is another possible strategy for reducing the 
toxicity [96], in the case of anthracyclines nuclear targeted and Non-nuclear 
targeted are two kinds of strategies concerned in the development of non-toxic 
chemotherapeutic agents. Analogues such as Methoxymorpholinyl doxorubicin 
(MMDX), sabarubicin and N-Benzyladriamycin-14-valerate now under develop-
ment to reduce the toxicity caused by DOX. In which, MMDX is nuclear-targeted 
analogue activated by the liver enzyme cytochrome P450 3A and metabolize into a 
cytotoxic metabolite and degrades slowly [103]. Based on gene therapy expression 
of cytochrome enzyme activity increased, cytochrome increases the therapeutic 
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potency of the DOX. The sabarubicin (disaccharide analogue) is also another 
nuclear targeted molecule that has improved efficiency especially used in case of 
lung and gynaecological cancer [104]. This stimulates the NF-kB transcription 
factor, which happens earlier as DNA is involved with multiple tumorogenesis, 
regulating the expressions of differentiation, variations, cell adhesion and apoptosis 
[105]. N-Benzyladriamycin-14-valerate is a non-nuclear target molecule obtained 
by modification of the C-3 amino group and the C-14 position [106]. The com-
pound has comparable activity to DOX but is theoretically more effective than DOX 
by activating the protein kinase enzyme resulting in cardio-protective activity.
4. Conclusion
Even DOX used for treating several types of cancers as a result of its wide 
range of pharmacological activities, but at the same time it causes a wide range of 
side effects. The major side effects caused by DOX are: carditoxicity, neuropathy, 
hepatotoxicity, nephrotoxicity, alopecia, typhlitis, myelosuppression, neutropenia, 
anaemia, and thrombocytopenia. DOX increasing the oxidative stress, decrease 
the GSH, vitamin E levels, and activates the NF-kB levels causes’ hepatotoxic-
ity. Besides, it interferes with the glandular podocytes of the kidney and cause 
nephropathy. Also, it induces generation of MDA, TBARS, and HNA which decrease 
the mitochondrial activities and increase in ROS generation causes cell necrosis. 
Moreover, it causes induction of brain natriuretic peptides, atrial natriuretic 
peptides genes, mono oxygenases, cytochrome P genes; binds to the cardiolipin, 
the increase in TLR-4 expression, generation of ROS led to several pathological 
changes in myocytes causes cardiomyopathy. Several strategies are made to manage 
and decrease DOX’s cardiotoxicity effects, includes a change in the dosage forms for 
efficacious delivery systems, administration along with anti-oxidants, DZR, diuret-
ics and β-adrenergic agents, and development of different analogues for increasing 
the efficiency of DOX.
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